Skip to content

Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease

Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03648398
Acronym
EDUMICILOR
Enrollment
50
Registered
2018-08-27
Start date
2021-01-29
Completion date
2023-04-01
Last updated
2021-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease, Ulcerative Colitis

Keywords

Therapeutic education program, Online

Brief summary

EDUMICILOR is a monocentric prospective pilot study for patients with inflammatory bowel disease (IBD). During the study, patients will participate in an online therapeutic education program. They will first have an appointment with a nurse to establish a personalized educational diagnosis. Then they will participate in the online therapeutic education program for about 6 months (depends on the educational needs, expectations and patient's availabilities). The main objective of this study is to assess the feasibility of an online therapeutic education program for IBD patients.

Interventions

OTHEREDUMICILOR

Patients will participate in the online therapeutic education program for about 6 months

Sponsors

Central Hospital, Nancy, France
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female (age ≥ 18 years old) * Patients with established Crohn's disease or ulcerative colitis diagnosis * Patients who own the equipment to participate in the online therapeutic education program (computer, webcam….) * French speaking patients * Patients who cannot attend regular therapeutic education sessions at the hospital * Patients able to understand the information provided to them and to give written informed consent for the study

Exclusion criteria

* Patient who has not given his/her consent to participate

Design outcomes

Primary

MeasureTime frameDescription
Frequency of participation in the online therapeutic education program6 monthsPatients must participate in at least 80% of therapeutic education program sessions and connect to at least one video or one serious game.

Secondary

MeasureTime frameDescription
Score of the short Inflammatory Bowel Disease Questionnaire (short-IBDQ)6 monthsThe short-IBDQ will assess the quality of life before and after the online therapeutic education program.
Score of the Inflammatory Bowel Disease Disability Index (IBD Disability Index)6 monthsThe IBD Disability index will be used to assess disability before and after the online therapeutic education program.
Score of the Crohn and Colitis Knowledge Score6 monthsThe Crohn and Colitis Knowledge Score will assess the impact of the online therapeutic education program on achieving educational objectives.
Score of the Girerd Scale6 monthsThe Girerd Scale will be used to assess the level of adherence to prescribed drugs before and after the online therapeutic education program.
Score of a satisfaction survey on the online therapeutic education program6 monthsThis survey will identify the advantages and disadvantages of an online therapeutic education program.
Score of the Hospital Anxiety and Depression Scale6 monthsThe Hospital Anxiety and Depression scale will assess the anxiety and depression level before and after the online therapeutic education program.

Countries

France

Contacts

Primary ContactMuriel Veltin
muriel.veltin@micilor.com0033383154187

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026